Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]

Factors influencing response to blinatumomab in relapsed/refractory ALL

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Factors influencing response to blinatumomab in relapsed/refractory ALL ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

DNMT3A R882 mutations promote chemoresistance and residual disease in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )

First randomised evidence for kinase inhibitor activity in acute myeloid...

Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany

First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )

Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma

Prof Yilong Wu - President of the Chinese Society of Clinical Oncology

Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma ( Prof Yilong Wu - President of the Chinese Society of Clinical Oncology )

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma

Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

ASCO 2015: Latest developments in multiple myeloma

Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos

ASCO 2015: Latest developments in multiple myeloma ( Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos )

ASCO 2015: Latest in chronic lymphocytic leukaemia

Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos

ASCO 2015: Latest in chronic lymphocytic leukaemia ( Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos )

Subgroup analysis of molecular markers in phase III study of high risk low...

Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany

Subgroup analysis of molecular markers in phase III study of high risk low-grade glioma ( Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany )

Advanced DNA sequencing test used to match rare cancers

Dr James Doroshow, Dr Keith Flaherty and Dr Barbara Conley

Advanced DNA sequencing test used to match rare cancers ( Dr James Doroshow, Dr Keith Flaherty and Dr Barbara Conley )

ASCO 2015: Latest developments in prostate cancer treatment

Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi

ASCO 2015: Latest developments in prostate cancer treatment ( Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi )

Raloxifene retained approximately 81% of the effectiveness of tamoxifen in...

Dr Lawrence Wickerham - NRG Oncology Research Group, Pittsburgh, USA

Raloxifene retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer ( Dr Lawrence Wickerham - NRG Oncology Research Group, Pittsburgh, USA )

Next generation inhibitors help overcome problems of resistance in ALK positive...

Dr Ross Camidge - University of Colorado, Denver, USA

Next generation inhibitors help overcome problems of resistance in ALK positive lung cancer ( Dr Ross Camidge - University of Colorado, Denver, USA )

More from ecancer